ArticleCancer2019
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Identifying, handling and impact of immortal time bias on addressing treatment effects in observational studies using routinely collected data.BMC medical research methodology · 2025Pooled it
- SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Guideline
- Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis.World journal of urology · 2020Pooled it
- Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder.Oncology research · 2026Article
- Grading of bladder cancer: updates, controversies and practical solutions.Histopathology · 2026Review
- Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer.Current treatment options in oncology · 2025Review
- Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.European urology · 2025Article
- Predicting variant histology in bladder cancer: the role of multiparametric MRI and vesical imaging-reporting and data system (VI-RADS).Abdominal radiology (New York) · 2025Article
- Frequency and Characterization of Rare Histologic Subtypes in Canine Invasive Urothelial Carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Article
- A Systematic Literature Review of Real-World Treatment Effectiveness and Economic and Humanistic Burden in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy.ClinicoEconomics and outcomes research : CEOR · 2025Review
- Letter to the editor for the article "Evaluation of histological variants of upper tract urothelial carcinoma as prognostic factor after radical nephroureterectomy".World journal of urology · 2024Article
- MRI-based automated machine learning model for preoperative identification of variant histology in muscle-invasive bladder carcinoma.European radiology · 2024Article
- One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.Current treatment options in oncology · 2024Review
- P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation.Cancers · 2023Article
- Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.Investigative and clinical urology · 2023Review
- Article
- Prognostic value of the sarcomatoid component in bladder cancer: A propensity score matching study.Oncology letters · 2023Article
- Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of adjuvant chemotherapy (AC) in pure urothelial carcinoma of the bladder is established. Regarding variant histology, there is a gap in knowledge concerning the optimal treatment after radical cystectomy (RC). The objective of this study was to assess the effect of AC on overall survival (OS) in patients who had pure urothelial carcinoma, urothelial carcinoma with concomitant variant histology, or another pure variant histology.
methodsWithin the National Cancer Data Base, 15,397 patients who underwent RC for nonmetastatic, localized carcinoma of the bladder and had positive lymph nodes (T2N+) or locally advanced stage (≥T3N0/N+) were identified, excluding those who had previously received neoadjuvant chemotherapy. Multivariable Cox regression models were used to examine the specific effect of AC on OS stratified by each distinct histologic subtype, including pure urothelial carcinoma, micropapillary or sarcomatoid differentiation, squamous cell carcinoma, adenocarcinoma, and neuroendocrine tumors. To account for immortal time bias, Cox regression analyses and Kaplan-Meier analyses were conducted with a landmark at 3 months.
resultsIn multivariable landmark analyses, AC compared with initial observation was associated with an OS benefit for patients who had pure urothelial carcinoma (hazard ratio, 0.87; 95% confidence interval, 0.82-0.91), whereas no differences were observed with regard to those who had variant histology.
conclusionsMultivariable Cox regression landmark analysis revealed a survival benefit from AC for patients with a pure urothelial carcinoma. However, a survival benefit of AC for patients who had urothelial carcinoma with concomitant variant histology or other pure variant histology was not demonstrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.